SAN FRANCISCO – A panel spanning regulator, payer, provider and academic interests celebrated the rapid proliferation of diagnostics based on emerging kinds of data that could enable more precise, earlier and better patient treatment. Starting with genomics, this data intensity has rapidly proliferated into all sorts of 'omics analyses, including proteomics, pharmacogenomics, metabolomics and microbiomics.